Institute for Bioscience and Biotechnology Research Awarded $6.9M to Design and Test a Vaccine to Combat Hepatitis C
The National Institute of Allergy and Infectious Disease (NIAID) awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes Hepatitis C, an illness that affects an estimated 71 million people worldwide. Hepatitis C Virus...
FDA Funds Collaborative Project to Develop New Approaches to Assess the Quality of Oligonucleotide Therapies
Dr. Jace Jones (UM School of Pharmacy), jointly with co-PIs Dr. Steven Fletcher (UM School of Pharmacy), Dr. Michael Cummings (University of Maryland College Park) and Dr. Robert G Brinson (NIST-IBBR), was recently awarded a grant from the FDA Center for Drug Evaluation and Research to develop and evaluate new...
UMD Bioengineers Awarded $1 Million Moore Foundation Grant to Advance Bioelectronic Technology
University of Maryland (UMD) bioengineers were awarded a $1 million Gordon and Betty Moore Foundation grant to advance technology that could bridge the gap between electronic devices and biology. This work, led by researchers within Maryland’s Fischell Department of Bioengineering (BIOE), Institute for Bioscience and Biotechnology Research (IBBR), and Robert...
IBBR is a joint research enterprise of the University of Maryland, College Park, the University of Maryland, Baltimore, and the National Institute of Standards and Technology.
IBBR leverages state-of-art integrative methods for bioanalytical, biophysical and structural characterization of biomolecules: cryo-electron microscopy, nuclear magnetic resonance, x-ray crystallography, small angle neutron and x-ray scattering and mass spectrometry.
IBBR researchers seek to advance therapeutic development, biomanufacturing, and state-of-the-art measurement technologies, to support accelerated delivery of safe and effective medicines to the public.
IBBR is a major initiative and supported in part by the University of Maryland Strategic Partnership: MPowering the State (MPower) , an initiative designed to achieve innovation and impact through collaboration.
Sophisticated state-of-the-art instrumentation and facilities, and in-house expertise located in shared space and dedicated to advance research, support collaboration and foster innovation of methods. Instrumentation and facilities include tools for high-resolution structural biology, bioanalytical and biophysical measurement, protein engineering and cell culture, advanced computation including artificial intelligence and deep learning methods, and general laboratory services. These capabilities and advanced training are available to IBBR scientists and collaborators.
IBBR Postdoc Program
The IBBR Postdoc Program (IPP) focuses on collaborative research involving basic science and technology development that advances therapeutic development, vaccine development, and biomanufacturing. IPP Fellow project teams are designed with a combination of the IPP Fellow career goals and priorities of project mentors who can be from academic, government, and/or industrial laboratories throughout the University of Maryland, NIST and the I-270 corridor.
IBBR is home to NMRPipe, a popular collection of programs and scripts for manipulating multidimensional Nuclear Magnetic Resonance (NMR) data. The use of NMRPipe is noted in roughly 40% of all NMR structures accepted into the Protein Data Bank.
Wednesday, October 5, 2022 - 11:00am
Monday, October 17, 2022 - 11:00am
University of Maryland, College Park
Monday, October 24, 2022 - 11:00am
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.
Anti-COVID antibody therapeutics have been developed but not widely used due to their high cost and escape of neutralization from the emerging variants. Here, we describe the development of...
Antibody interfaces revealed through structural mining.
Antibodies are fundamental effectors of humoral immunity, and have become a highly successful class of therapeutics. There is increasing evidence that antibodies utilize transient homotypic...
Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.
Overexpression of the anti-apoptotic BCL-2 proteins is associated with the development and progression of a range of cancers. Venetoclax, an FDA-approved BCL-2 inhibitor, is fast becoming the...
Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models.
Prostate cancer (PCa) relies in part on AR-signaling for disease development and progression. Earlier, we developed drug candidate galeterone, which advanced through phase 2-clinical trials in...
Biopharmaceutical Manufacturing Readiness Levels (BRL) - A Shared Vocabulary for Biopharmaceutical Technology Development and Commercialization.
The Manufacturing Readiness Levels (MRLs) developed by the Department of Defense (DoD), are well established tools for describing the maturity of new technologies resulting from government...